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Background: In clinical practice, unexpected diagnosis of colorectal cancer in young patients requires prompt surgery,
thus genetic testing for Lynch Syndrome is frequently missed, and clinical management may result incorrect.
Methods: Patients younger than 50 years old undergoing colorectal resection for cancer in the period 1994-2007 were
identified (Group A, 49 cases), and compared to a group of randomly selected patients more than 50 (Group B, 85
cases). In 31 group A patients, immunohistochemical expression analysis of MLH1, MSH2 and MSH6 was performed;
personal and familial history of patients with defective MMR proteins expression was further investigated, searching for
synchronous and metachronous tumors in probands and their families.
Results: Fifty-one percent of patients did not express one or more MMR proteins (MMR-) and should be
considered Lynch Syndrome carriers (16 patients, group A1); while only 31.2% of them were positive for
Amsterdam criteria, 50% had almost another tumor, 37.5% had another colorectal tumor and 68% had
relatives with colorectal tumor. This group of patients, compared with A2 group (< 50 years old, MMR+)
and B group, showed typical characteristics of HNPCC, such as proximal location, mucinous histotype, poor
differentiation, high stage and shorter survival.
Conclusions: The present study confirms that preoperative knowledge of MMR proteins expression in
colorectal cancer patients would allow correct staging, more extended colonic resection, specific follow-up
and familial screening.Background
Hereditary non-polyposis colorectal cancer (HNPCC), also
known as Lynch Syndrome [1], is an autosomal-dominant
syndrome accounting for 3-5% of colorectal cancer cases
[2,3], predisposing to female reproductive and urinary
tract cancers, as well as other extracolonic tumors [4,5]. It
is actually known that Lynch Syndrome is caused by an
inherited or acquired mutation that inactivates one or
more genes for the mismatch repair (MMR) proteins,
which normally recognize the wrongly incorporated* Correspondence: baiocchi@med.unibs.it
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reproduction in any medium, provided the ornucleotide and replace it with the correct one, leading to
accumulation of cellular mutations and thus greatly in-
creasing the likelihood of malignant transformation [6,7].
Almost five DNA MMR genes (MLH1, MSH2, MSH6,
PMS2 and PMS1) have been individuated as possible mu-
tation sites, and their proteins unexpression or mutation,
have been investigated as possible causes of Lynch Syn-
drome. Patients with MMR genes mutation and protein
absence or inactivation have a lifetime risk of CRC of
70-80% if no regular endoscopic screening is performed,
with a mean age of CRC diagnosis of 44 years [4].
The diagnosis of Lynch Syndrome generally requires
three steps, including a review of family history of cancer,
the cancer specimen analysis and the genetic analysis, i.e.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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genes [8-10]. In clinical practice, however, outside the fam-
ilies known to be affected by Lynch Syndrome, the most
frequent situation is the unexpected diagnosis of colorectal
neoplasm in a young patient, for which a treatment program
should be scheduled as soon as possible, not allowing a
proper genetic study before surgery. In these cases, if the pa-
tient is not correctly diagnosed as a Lynch Syndrome bearer,
treatment may finally result inappropriate in terms of com-
pleteness of preoperative staging and extension of colonic
removal.
The aim of the present study is to determine if a pre-
operative diagnosis of HNPCC by MMR proteins expression
analysis could affect treatment decisions, leading to a better
management.
Methods
All colorectal resections for cancer performed at the
Surgical Clinic of the University of Brescia in the period
1994-2007 were retrospectively analyzed. Every patient
entered into a scheduled program of clinical and instru-
mental follow-up. Our object was the comparison between
patients under 50 years (Group A), and a sample of 85
randomly selected patients (which follow-up was recently
updated for another study), more than 50 (included) years
old (group B). The following parameters were recorded:
age, sex, clinical presentation (symptomatic or not), opera-
tive treatment (resection of a colonic segment or extended
surgery, including at least two segments or subtotal/total
colectomy), cancer site (proximal to the transverse colon
included, or distal), histotype (mucinous or not), staging
(T1-2 or T3-4), grading (G1-2 or G3), disease-free and
overall survival rates.
In group A, immunohistochemical analysis on histo-
logical samples derived from preoperative endoscopic biop-
sies and/or removed pieces was performed, to determine
the loss of expression of 3 MMR proteins (MLH1, MSH2
and MSH6). After retrieving the paraffin blocks, 8 micron
thick sections were obtained and stained with hematoxylin
and eosin. The slides were placed in a microwave oven for
5 minutes in jet mode (full power) twice, and 3 more times
for 5 minutes at 750 W power and lastly incubated for
40 minutes. Anti-MLH1 Mouse antibody clone G168-15
BD, at 1:30 dilution (Biosciences CompanyTM, Toronto,
Ontario, Canada, code 551092), anti-MSH2 Mouse anti-
body, clone G216-1129, at 1:20 dilution (Biosciences
CompanyTM, Toronto, Ontario, Canada, code 556349)
and the Anti-MSH6 Mouse antibody, clone 44 (Zymed
Laboratories Inc.TM, San Francisco, California, USA,
code 08-1374) have been employed. For antigen unmask-
ing the EDTA buffer at pH 8, 0.1 M was used. Data about
MMR were expressed as dichotomous variables (yes/no),
even though in 8 cases a diagnostic doubt was due to an
insufficient but not entirely absent expression of theprotein. The cases with preserved expression were consid-
ered normal, those without expression (as well as those
with diagnostic doubt) were not. In the present work it
was not taken into account what has been previously
demonstrated: the absent expression of MSH6 is associ-
ated in 5% of cases with impaired quality (but with normal
immunohistochemical expression) of MSH2, in which
case it would be useful to proceed with its genetic analysis
[11-13]. Furthermore, in the present work we did not
investigate micro satellite instability (MSI) and gene
sequences of MMR.
Patients with complete or partial lack of expression
(group A1) were compared to patients with preserved
expression (group A2) of one or more MMR protein,
concerning clinical, pathological and survival features. In
patients belonging to group A1, the personal and family
history was deeply assessed, up to the previous second
generation (brethren, parents, uncles, grandparents and
grandparent’s brethren) and first subsequent generation
(children and brethren’s children), in accordance with
the Amsterdam II criteria [14]; for patients in which
such informations were not clearly available from the
analysis of medical supplies, telephone interviews were
conducted. All the relatives in the 4 generations and the
probands were investigated for every type of cancer, includ-
ing previous and metachronous ones; colorectal polyps
were considered as neoplasm if high-grade dysplasia was
documented. All the interviews were done in 2010, from
March to July, follow-up information being recorded up to
12/12/2009.
Statistical analysis was performed by Chi square test for
dichotomous variables and Student's t test for continuous
variables. Survival curves were constructed with the actu-
arial model, and comparison between curves was carried
out by the method of Mantel-Haenzn.
This study was approved by the University Institutional
Board Ethics Committee (Department of Clinical and
Experimental Sciences).
Results
The entire series of colorectal resections for cancer in
the period under investigation consists of 814 patients.
Forty-nine patients less than 50 years old were identified
(group A), with a mean age of 41 years; 27 were males
and 22 females. Table 1 compares clinical and patho-
logical features of Group A patients with those of
patients older than 50 years (Group B); the former had a
more frequently symptomatic tumor, the most reported
symptoms being abdominal pain (43% of cases), bleeding
(35% of cases), occlusion (14%) and palpable abdominal
mass (8% of cases). Moreover, more undifferentiated
tumors and advanced stages were identified in group A
patients; however, the prognosis was not significantly
different (Figure 1).
Table 1 Comparison between group A (<50 years) and
group B (> 50 years).
Group A (49) Group B (85) p
Age (mean) 40,2 66,0 0.001
Symptoms 93,8% 62,3% 0.031
Extended surgery* 9,7% 9,4% 0.965
Proximal localization** 38,7% 34,1% 0.647
Mucinous 16,1% 14,1% 0.786
Advanced stage (T3-4) 61,3% 37,6% 0.023
Undifferentiated 32,2% 9,4% 0.0026
Disease free survival (mean) 73 m 81 m 0.78
Overall survival (mean) 79 m 89 m 0.86
*More than 1 segment colonic resection.
**Proximal to the transverse colon, included.
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patients; in 3 cases a final diagnosis of familial adenomatous
polyposis (FAP) was confirmed by genetic testing, while the
remaining 15 cases were not available for reevaluation or
were used for other investigations. In 8 patients out of 31
available cases, both endoscopic biopsies and surgical speci-
mens were analyzed, and the 2 determinations were always
concordant. Fifteen patients had a normal expression of
MLH1, MSH2 and MLH6, 8 patients had a doubtful expres-
sion (25.8%), and 8 patients showed markedly deficient ex-
pression of at least one MMR protein (25.8%). The clinical
features of the 16 patients considered as having altered im-
munohistochemical expression of MMR protein(s) are as
follows: 5/16 patients (31.2%) belonged to Amsterdam and
16/16 patients belonged to Bethesda criteria (due to the
inclusion in group A of only younger than 50 year old cases)
[15,16]; 8/16 patients (50%) had an association with other
synchronous or metachronous extracolonic tumors; in 11/
16 cases (68.7%) another colorectal cancer developed in the74,2
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Figure 1 A vs B overall survival (p = NS).4 generations analyzed for each patient; finally, 6/16
patients (37.5%) developed another subsequent colonic
neoplasm (Table 2). A total of 37 cases of cancer were
diagnosed, including colorectal (19), endometrium (6),
breast (2), kidney (2), Vateri papilla (1), prostate (3),
skin cancers (3) and lung (1).
Table 3 reports the comparison between HNPCC cases
(group A1) and general population (Group B). In group
A1 the following clinical presentations were found: high
percentage of proximal, mucinous, poorly differentiated
and high stage tumors. The survival was significantly
lower for Group A1 than for Group B (p = 0.048, Figure 2)
and group A2 (p = 0.049) patients.
Discussion
Colorectal cancer in Lynch Syndrome have distinctive
clinical features that are well known in literature, such as
younger age at presentation, proximal location, mucinous
differentiation, advanced stage, associated extracolonic
tumors and better stage-normalized prognosis [2,6,17].
However, even if well-known management guidelines
are available, in daily clinical practice most frequently a
diagnosis of colon cancer in a young patient is not im-
mediately followed by a routine assessment for Lynch
Syndrome - except in cases in which the diagnosis is made
during a screening program in a family known for bearing
the genetic mutation - thus patient does not receive
specific treatment. In particular, the surgeon may not per-
form a more extensive surgery on the colon (total or sub-
total colectomy [18]), eventually associated in women with
prophylactic hysterectomy or hystero-ovariectomy, and
may not look for synchronous extracolonic tumors [19,20].
At most, the study is left to postoperative time. The main
reason of this common practice is related to the delay of
cure required to carry out proper genetic investigations. In
fact, as demonstrated by this series of patients undergoing
colonic resection for cancer before 50 years of age, in
young patients the cancer is often symptomatic for abdom-
inal pain, bleeding, obstruction or palpable abdominal
mass (over 90% of our patients). Furthermore, waiting few
weeks may be not tolerable from a psychological point of
view. Thus, our series represents the current clinical prac-
tice, in which most frequently a correct recognition of
Lynch Syndrome failed.
Compared to patients older than 50 years, young patients
(Group A) showed a statistically significant difference in
the rate of undifferentiated and high stage tumors (Table 1).
This is easily explained by the fact that colon cancer diag-
nosis are often late in young people, in a symptomatic
stage. Accordingly, patients in group A seem to have a
worse prognosis (not statistically significant, Figure 1).
Other typical features of Lynch Syndrome (mucinous
histology and proximal location), while more frequent,
were not significantly represented in this group. The
Table 2 Deficiency of mismatch repair protein expression (group A1)
Case MLH1 MSH2 MSH6 AMST BETH Other tumors* Familial history** Colon recurrence
1 - + - YES YES NO YES YES
2 - + + NO YES YES YES YES
3 + - + NO YES NO NO NO
4 + + - NO YES YES YES NO
5 + + - NO YES YES NO NO
6 - + +/- NO YES NO YES YES
7 + - + YES YES NO NO NO
8 - +/- + NO YES NO YES NO
9 + + +/- NO YES YES YES NO
10 +/- + +/- YES YES NO NO NO
11 + + +/- NO YES YES YES YES
12 +/- + +/- YES YES NO NO NO
13 +/- + + NO YES YES YES YES
14 + + +/- NO YES YES YES YES
15 + + +/- NO YES YES YES NO
16 + + +/- YES YES NO YES NO
+/- Partial expression of the protein.
*Both synchronous and metachronous.
**Four generations have been analyzed (see the text).
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was also similar in groups A and B.
The aim of the present work was therefore to analyze
the expression of MMR proteins in young patients by
immunohistochemical determination of MLH1, MSH2
and MSH6, in order to identify those actually belonging
to a Lynch Syndrome family.
A limited sample of 31 cases was available for the analysis.
Out of these, 16 had a clearly deficient or absent expression
of at least one MMR protein, and thus were HNPCC-
related colorectal cancer cases (Group A1). This group isTable 3 Comparison between group A1 (<50 years, MMR-, thu
Group A1 (16)
Age (mean) 40
Symptoms 100%
Extended surgery* 43.7%***
Proximal localization** 43,7%
Mucinous 56.2%
Advanced stage (T3-4) 75%
Undifferentiated 31,2%
Disease free survival (mean) 63,9 m
Overall survival (mean) 64,5 m
Disease free survival (mean) 63,9 m
Overall survival (mean) 64,5 m
*More than 1 segment colonic resection.
**Proximal to the transverse colon, included.
***Including resections for metachronous tumors.indeed more homogeneous than the whole group A regard-
ing clinical characteristics of malignancies, as shown in
Table 3: these patients had more frequently a proximal and
mucinous tumor, and their prognosis was significantly worse
than for group B (Figure 2); this is partly in disagreement
with the literature, and may be explained by two reasons:
first, all group A1 patients were diagnosed because of symp-
toms, thus with an advanced stage, while the data reported
in the literature usually refer to patients known to be
affected by Lynch Syndrome, thus including a relevant pro-
portion of cases diagnosed through screening investigations;s HNPCC cases) and group B (> 50 years)
Group B (85) Group A2 (33) P
66 0.001
62% 0.031
9,4% 0.032
34,1% 0.46
14,1% 0.047
36,4% 0.0042
9,4% 0.0167
81 m 0.057
89 m 0.048
78,2 m 0.061
81,6 m 0.049
62,5
43,7
37,5 37,5
18,7
82,3
70,6
63,5
50,6
37,6
0
20
40
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80
100
0 1 2 3 5 10
OS group A1 OS Group B
Years 0 1 2 3 5 10
A1 100%=16 62,5%=10 43,75%=7 37,5%=6 37,5%=6 18,75%=3
B 100%=85 82,35%=75 70,588%=60 63,529%=54 50,58%=43 37,647%=32
Figure 2 A1 versus B overall survival (p = 0.044).
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received proper treatment, including early research and
treatment of other cancers and extended colectomy to
prevent colon cancer recurrence. Indeed, the difference in
survival between A1 (< 50 years, MMR-) and A2 (<50 years,
MMR+) remains significant because those groups are more
homogenous, being both very young and having both a
great proportion of advanced symptomatic cases.
Analyzing in detail the clinical history, before and after
the intervention, half of these 16 patients did previously
have or subsequently developed other tumors; in particular
37.5% developed metachronous colonic tumors requiring
redo-surgery. Only 1 out of 16 MMR deficient patients
underwent a primary extended colectomy; 5 our of 15
patients receiving primary segmental resection subsequently
developed a colonic recurrence. Prophylactic subtotal colec-
tomy may be proposed as alternative to surveillance colon-
oscopy for individuals with confirmed mutations. Syngal
and Collegues used a decision-analysis model to evaluate life
expectancy and quality-adjusted life expectancy in 25 years
old patients with a confirmed mutation undergoing prophy-
lactic surgery, compared with colonoscopy surveillance.
They showed that, although both approaches offer only a
modest survival benefit, immediate procto-colectomy or
subtotal colectomy was superior to surveillance, with an ex-
pected gain in life expectancy of 15.6 and 15.3 years after
the immediate proctocolectomy or subtotal colectomy re-
spectively, compared with 13.5 years for surveillance [21]. In
a recent paper, Parry and Colleagues found that 0% and 22%
respectively of patients receiving extended and segmental
colonic resection had a metachronous colorectal cancer,
with a risk reduction of 31% (95% CI 12% to 46%; p = 0.002)
for every 10 cm of bowel removed [18].
These data clearly show at what extent a correct recog-
nition of Lynch Syndrome may influence the management
of affected patients, both in terms of diagnostic approach(including preoperative staging and follow-up) and surgi-
cal strategy. On the other hand, clinical diagnosis based
on medical history, including a precise picture of the
genealogical tree for at least four generations, referring to
the Amsterdam and/or Bethesda criteria, seems from our
study to be inadequate: we identified only 31% of HNPCC
patients by Amsterdam criteria, while only about half of
those who fulfilled Bethesda criteria (i.e. all our patients
Group A) were affected by HNPCC. The immunohisto-
chemical determination of MLH1, MSH2 and MSH6 pro-
teins has been simple, cheap and fast in this series.
Moreover, according to our data, the biopsy samples can
be used for this purpose in the preoperative period. In
all the 8 cases in which the analysis was done both on
preoperative biopsies and surgical specimen, there was
a complete agreement in MMR proteins expression.
Similar results have been recently reported by Warrier
and Colleagues in a series of 33 germ-line positive mu-
tation carriers patients in which the sensitivity of the
endoscopic biopsy in predicting the germ-line status
was 94.9% (95% CI 80.4-98.3) [22].
Lack of PMS2 immunohistochemical analysis and MSI
determination are main limitations of the present study;
however, some recent proposal to reduce the number of
MMR proteins analysis to lower costs in daily practice is
appearing; for instance, Shia and Collegues provided evi-
dence that a 2-antibody panel is as effective as the current
4-antibody panel in detecting DNA mismatch repair protein
abnormalities [23]. MSI is a very useful diagnostic tool, com-
plementary to the immunohistochemical determination of
MMR proteins expression, and it can be conducted rapidly
on the biopsy material too. Furthermore, MSI analysis has a
93% sensitivity in detecting MMR deficiency in MMR
mutation carriers [24]. However, compared with MSI
analysis, immunohistochemistry has the additional advan-
tage of identifying the MMR gene which is most eligible
for DNA analysis [25]. On the other hand, MMR proteins
belong expressed in case of protein truncation, such as
frame shift, splice site mutations and large genomic rear-
rangements: the abnormal protein may have a loss of
function but be still detected with immunohistochemisty
[11-13]. Furthermore, this work did not provide an imple-
mentation of genetic testing, which is considered time-
consuming in the preoperative setting [15].
Conclusions
The retrospective analysis of a 20 years series of colonic re-
sections for malignancy, specifically focused on patients
which were diagnosed to have a colorectal cancer less than
50 years old, confirms that the preoperative identification of
patients with Lynch Syndrome, by the immunohistochemi-
cal determination of the MMR proteins expression, may
have a great immediate clinical relevance [26], leading to a
correct surgical and global care strategy.
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